Revumenib (SNDX-5613) is a first-in-class, effective and selective Menin-MLL binding inhibitor with Ki of 0.15 nM. Revumenib (SNDX-5613) can be used to study MLL gene rearrangement in acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Empesertib (BAY1161909) is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase (IC50 of < 1 nM), with potential antineoplastic activity.
Avexitide (Exendin 9-39) is a specific and competitive GLP-1 receptor antagonist.
Masitinib (AB-1010) mesylate is a potent, orally bioavailable and selective inhibitor of c-Kit, IC50 of 200 nM for human recombinant c-Kit. It also inhibits PDGFRα/β, LynB with IC50 values of 540, 800 and 510 nM.
Glp-1 (7-37) is an intestinal insulin hormone that enhances glucose-induced insulin secretion.
Benznidazole is a nitroimidazole derivative having an antiprotozoal activity by interfering with parasite protein biosynthesis, influencing cytokines production and stimulating host phagocytosis.
L-Alanyl-L-glutamine, for cell culture is cell culture grade proglutide, a stabilized form of L-glutamine.
PF-5274857 is a novel Smoothened antagonist, inhibits Hedgehog signaling with IC50 and Ki values of 5.8 nM and 4.6 nM, respectively.
Ginsenoside Rk1 is a high-temperature processed extract of ginseng. Ginsenoside Rk1 has anti-inflammatory effects and inhibits Jak2/Stat3 signaling pathway and NF-κB activation.